vaccine – Global Reproductive Health at Duke

HIV Patients Sue Government Over Lack of Septrin

December 3, 2018December 3, 2018 by Faith OtewaNo Comments

Co-trimoxazole preventive therapy is a feasible intervention for people living with HIV. It works to reduce HIV-related morbidity and mortality through an off-patent drug, which is widely available in resource-limited settings. The World Health Organization (WHO) conditionally recommends the use of co-trimoxazole as treatment for opportunistic infections in people living with HIV/AIDS. In Uganda, previous reports by the State Minister for Health stated that there was a funding shortage for the drug. The Global Fund, with headquarters in Geneva, Switzerland has since stepped in to provide all funds for the drugs available from July 2018 onwards. This is good news, as daily intake of co-trimoxazole relieves symptoms and prolongs life for people living with HIV/AIDS. However, a human rights organization and two people living with HIV have sued the Ugandan Government and the National Medical Stores (NMS) for alleged failure to supply public health centers with septrin as one of the essential drugs for treatment of AIDS for the months of March...

Eradicating Human Diseases: Opportunities and Risks

December 1, 2018December 1, 2018 by Jessica WilliamsNo Comments

The Director of the Center for Global Reproductive Health, Dr. Megan Huchko, participated in a panel on November 28th entitled "Eradicating Human Diseases: Opportunities and Risks." Dr. Gavin Yamey (Director for the Center for Policy Impact in Global Health) moderated the event, which featured Dr. Christopher Plowe (Director of the Duke Global Health Institute), Dr. Lavanya Vasudevan (Assistant Professor in Community and Family Medicine) and Dr. Osondu Ogbuoji (Deputy Director of the Center for Policy Impact in Global Health) as additional panelists. While the panelists disagreed on the definition of eradication, they all commented upon 'donor fatigue' and the economic and political difficulty of completing eradication as cases dwindle. The panel discussed the difficulty global health programs face in second-world countries, which don't benefit from the same economic resources as first-world countries or as many donations as third-world countries. The panelists stressed the importance of continued screenings, especially in the case of cervical cancer, and emphasized the necessity of childhood vaccinations....

The KCHSSIP 2018-2022 Validation Meeting

November 30, 2018November 30, 2018 by Faith OtewaNo Comments

The KCHSSIP (Kisumu County Health Sector Strategic and Investment Plan) 2018-2022 validation meeting held at the Acacia Hotel on 9th Nov 2018 saw the Kisumu County Health Department and a consortium of partners come together to finalize a plan, which is based on data from county health services over the last 5 years, as well as experiences and lessons learned during implementation of the first strategic plan from 2013 to 2017. The plan attempts to effectively position the County Health Department in the correct contexts of the health system pillars: human resources for health, health technology and infrastructure, pharmaceutical and medical supplies, health governance and leadership, health service delivery, health financing, health information system, health sector policies and context and health sector social outcomes. It also examines county health burdens such as malaria, HIV/AIDS, diarrheal diseases, skin diseases, pneumonia, tuberculosis and other respiratory diseases and non-communicable diseases. The document has gone through a process of stakeholder’s participation and input and is now...

Experimental HIV vaccine could move to human trials next year

June 25, 2018July 4, 2018 by Anna KatzNo Comments

An HIV vaccine could be closer than we think. A study published in Nature Medicine earlier this month highlights significant progress in efforts by scientists at the National Institutes of Health to develop an HIV vaccine. By targeting a vulnerable part of the virus, scientists were able to elicit antibodies that neutralized almost one-third of HIV strains in mice. The vaccine produced a similar neutralizing response in guinea pigs and rhesus monkeys, suggesting that their approach is promising. The researchers will continue to optimize the vaccine in the coming months, and anticipate beginning a preliminary human trial of the new vaccine regimen in late 2019. - Anna Katz, Communications Intern...

New study shows low, declining HPV vaccine follow-through in U.S.

June 14, 2018June 14, 2018 by Anna KatzNo Comments

Human papillomavirus (HPV) is one of the most common sexually transmitted infections, and causes about 31,500 cancers in the United States each year. It also has a vaccine--but many Americans aren't being vaccinated. The HPV vaccine is already underutilized in the United States, and a new study by researchers at the University of North Carolina found that HPV vaccine follow-through is declining over time. The vaccine, which is highly effective at preventing the development of abnormal cells that can progress to cervical cancer, is delivered in a series of doses. The Centers for Disease Control and Prevention (CDC) recommends that all children ages 11-12 should get two doses of the vaccine six to twelve months apart; adolescents older than 14 should get three shots over four months. Yet the survey of more than a million privately-insured Americans showed that vaccine follow-through declined from 2006 to 2014. The decrease was especially prominent among female patients, from 67% in 2006 to 38%...